CD274 and non-small cell lung carcinoma: TACTI-002 is a phase II study of eftilagimod-α in combination with pembrolizumab in patients not selected for PD-L1 expression with immunotherapy-naïve (first-line) and immunotherapy-refractory metastatic NSCLC and immunotherapy-naïve (second-line) patients with head and neck squamous cell carcinoma (HNSCC).